NervGen Pharma targets a neglected market with significant unmet needs, offering high-risk, high-reward potential if NVG-291 ...

Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

ReposiTrak posted strong Q3 growth and solid EPS potential, but high valuation limits upside and margin of safety. Find out ...

Welcome to the Money blog, Sky News' consumer and personal finance hub. Today: oil prices hit a two-month high after Israel attacked Iran and a Which? investigaton raises concerns over "dodgy" TV ...